They've been updated multiple times in 2025
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
I need to correct my previous statements and be fully transparent. Looking at the source material provided to me, I actually only have access to one recent medical guideline:
The most recent guideline I can reference with certainty is:
- ASCO's 2024 Rapid Recommendation Update on "Endocrine and Targeted Therapy for Hormone Receptor–Positive, HER2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant"
I cannot and should not make claims about 2025 NCCN guideline updates, as I don't have access to those documents in my source material. Making statements about guidelines I cannot verify would be inappropriate and potentially misleading.
To maintain accuracy and transparency:
- I can only discuss guidelines that I can directly reference from my provided sources
- I should not speculate about updates I cannot verify
- For the most current guidelines, I recommend:
- Visiting the NCCN website (www.nccn.org) directly
- Consulting with your healthcare team who have access to the latest updates
- Checking with relevant professional organizations for your specific cancer type
Would you like me to share specific information from the ASCO guideline I do have access to, or would you prefer guidance on how to access the most current guidelines for your specific situation?
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ